Haemophilus influenzae type b-Neisseria meningitidis serogroups C and y tetanus toxoid conjugate vaccine for infants and toddlers

Expert Review of Vaccines

Volumn 10, Issue 7, 2011, Pages 941-950

  Bryant, Kristina A ^a   Marshall, Gary S ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

conjugate vaccine; Haemophilus influenzae type b; infant immunization; Neisseria meningitidis

Indexed keywords

BACTERIAL VACCINE; DIPHTHERIA PERTUSSIS POLIOMYELITIS TETANUS HEPATITIS B VACCINE; DIPHTHERIA PERTUSSIS TETANUS HAEMOPHILUS INFLUENZAE TYPE B VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B NEISSERIA MENINGITIDIS SEROGROUPS C AND Y TETANUS TOXOID CONJUGATE VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MENHIBRIX; MENINGOCOCCUS VACCINE; MENITORIX; PENTACEL; PNEUMOCOCCUS VACCINE; POLYSACCHARIDE VACCINE; TETANUS TOXOID; UNCLASSIFIED DRUG;

ANTIBODY RESPONSE; ARTICLE; DRUG APPROVAL; DRUG CONJUGATION; DRUG MANUFACTURE; DRUG SAFETY; DRUG TOLERABILITY; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNOGENICITY; MENINGOCOCCOSIS; NEISSERIA MENINGITIDIS; PRIORITY JOURNAL; VACCINATION;

HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; INFANT; INFANT, NEWBORN; MENINGOCOCCAL VACCINES; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID; VACCINES, COMBINED; VACCINES, CONJUGATE;

EID: 80051501247     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.11.90     Document Type: Article

References (35)

1. Pollard AJ. Global epidemiology of meningococcal disease and vaccine effcacy. Pediatr. Infect. Dis. J. 23(Suppl. 12), S274-S279 (2004). (Pubitemid 44544509)
2. Kaplan SL, Schutze GE, Leake JA et al. Multicenter surveillance of meningococcal infections in children. Pediatrics 18, e979-e984 (2006). (Pubitemid 46393746)
3. Edwards MS, Baker CJ. Complications and sequelae of meningococcal disease in children. J. Pediatr. 99, 540-545 (1981). (Pubitemid 12232084)
4. Erickson LJ, De Wats P, McMahon J, Heim S. Complications of meningococcal disease in college students. Clin. Infect. Dis. 33, 737-739 (2001). (Pubitemid 32762952)
5. Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analyis. Lancet Infect. Dis. 10, 853-861 (2010).
6. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin. Microbiol. Rev. 19, 142-164 (2006). (Pubitemid 43157651)
7. Plotkin SA. Correlates of vaccine-induced immunity Clin. Infect. Dis. 47, 401-409 (2008).
8. Harrison LH, Totter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine 275, 851-863 (2009).
9. Swartley JS, Marfn AA, Edupuganti S et al Capsule switching of N. meningitidis. Proc. Natl Acad. Sci. USA 94, 271-276 (1997).
10. Cohn AC, MacNeil JR, Harrison LH et al Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin. Infect. Dis. 50(2), 184-191 (2010).
11. Gold R, Lepo ML, Goldschneider I et al. Clinical evaluation of group A and group C meningococcal polysaccharide vaccine in infants. J. Clin. Invest. 56, 1536-1547 (1975).
12. Campbell H, Borrow R, Salisbury D, Miller E. Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 27(S2), 820-829 (2009).
13. Trotter CL, Ramsay ME. Vaccination against meningococcal disease in Europe: review and recommendations for the use of conjugate vaccine. FEMS Microbiol. Rev. 31, 101-107 (2007). (Pubitemid 46058826)
14. Simpkines DB, Wood N, Jelfs J et al. Modern trends in mortality from meningococcocal disease. Pediatr. Infect. Dis. J. 28, 1119-1120 (2009).
15. CDC. Updated recommendations for use of meningococcal conjugate vaccines-Advisory Committee on Immunization Practices (ACIP), 2010. MMWR Morb. Mortal. Wkly Rep. 60, 72-76 (2011).
16. Rennels M, King J Jr, Ryall R et al. Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. 23, 429-435 (2004). (Pubitemid 38621482)
17. Keyserling H, Pina M, Hou V, Bhassily E, Reinhardt A. Immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine against serogroups A, C, Y and W-135 (MCV-4) in 9 to 15 month olds. Programs and Abstracts of the 44th Annual Meeting of the Infectious Diseases Society of America. Toronto, Canada (2006) (Abstract 640).
18. Snape MD, Perrett KP, Ford KJ et al. Immunogenicity of a tetravalent meningococcal conjugate vaccine in infants: a randomized trial. JAMA 299, 173-184 (2008).
19. Perrett KP, Snape MD, Ford KJ et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal vaccine infants. Pediatr. Infect. Dis. J. 28, 186-193 (2009).
20. Nolan T, Lambert S, Roberton D et al. A novel combined Haemophilus infuenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine 25(51), 8487-8499 (2007). (Pubitemid 350199589)
21. Habermehl P, Leroux-Roels G, Sänger R, Mächler G, Boutriau D. Combined Haemophilus infuenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2,3,4 months schedule with a fourth dose at 12 to 18 months of age. Hum. Vaccin. 6, 640-651 (2010).
22. Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection-serum bactericidal antibody. Vaccine 23, 2222-2227 (2005). (Pubitemid 40341456)
23. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. The role of humoral antibodies. J. Exp. Med. 129, 1307-1326 (1969).
24. Andrews N, Borrow R, Miller E. Validation of serological correlate of protection for meningococcal C conjugate vaccine by using effcacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10, 780-786 (2003). (Pubitemid 37129487)
25. Roush SW, Murphy TV. Vaccine Preventable Disease Table Working Group. Historical comparisons of morbidity and mortality for vaccine-preventable diseases in the United States. JAMA 298, 2155-2163 (2007). (Pubitemid 350106654)
26. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus infuenzae type b. J. Infect. Dis. 149(6), 1034-1035 (1984).
27. Käyhty H, Peltola H, Karanko V, Mäkelä PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus infuenzae type b. J. Infect. Dis. 147(6), 1100 (1983). (Pubitemid 13068358)
28. Marchant CD, Miller JM, Marshall GS et al. Randomized trial to assess immunogenicity and safety of Haemophilus infuenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr. Infect. Dis. J. 29, 48-52 (2010).
29. Marshall GS, Marchant CD, Blatter M et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus infuenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. Pediatr. Infect. Dis. J. 29, 469-471 (2010).
30. Nolan T, Richmond P, Marshall H et al Immunogenicity and safety of an investigational combined Haemophilus infuenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxid conjugate vaccine. Pediatr. Infect. Dis. J. 30, 190-196 (2011).
31. Bryant K, Marshall G, Marchant C et al. Immunogenicity and safety of H. infuenzae type b-N. meningitidis C/Y conjugate vaccine in infants. Pediatrics 127(6), e1375-e1385 (2011).
32. Bryant KA, McVernon V, Marchant CD et al. Immune response to measles, mumps, rubella (MMR) and varicella (V) vaccine coadministered with a fourth dose of Haemophilus infuenzae type b-Neisseria meningitidis serogroups C and Y (HibMenCY) vaccine in toddlers. Programs and Abstracts of the Pediatric Academic Societies' Annual Meeting. Vancouver, Canada (2010) (Abstract 2861.468).
33. Bryant K, Marshall GS, Marchant CD et al. Haemophilus infuenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY) was immunogenic with an acceptable safety profle in two Phase 3 trials. Programs and Abstracts of the 44th National Immunization Conference. Atlanta, GA, USA (2010) (Abstract 22739).
34. Marshall GS, Mesaros N, Aris E, Marchant CD, Blatter M, Miller JM. Persistence of immunity three years after an investigational Haemophilus infuenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid (HibMenCY-TT) conjugate vaccine. Programs and Abstracts of the 45th National Immunization Conference. Washington, DC, USA (2011) (Abstract 25219).
35. Vogel U, Claus H, Frosch M. Rapid serogroup switching in Neisseria meningitidis. N. Engl. J. Med. 342(3), 219-220 (2000). (Pubitemid 30051663)